↓ Skip to main content

Naproxen

Overview of attention for article published in Drugs, October 2012
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Good Attention Score compared to outputs of the same age (76th percentile)
  • Good Attention Score compared to outputs of the same age and source (68th percentile)

Mentioned by

patent
7 patents
wikipedia
2 Wikipedia pages

Citations

dimensions_citation
183 Dimensions

Readers on

mendeley
114 Mendeley
Title
Naproxen
Published in
Drugs, October 2012
DOI 10.2165/00003495-199040010-00006
Pubmed ID
Authors

Peter A. Todd, Stephen P. Clissold

Abstract

Naproxen is a nonsteroidal anti-inflammatory drug (NSAID) advocated for use in painful and inflammatory rheumatic and certain nonrheumatic conditions. It may be administered orally or rectally using a convenient once or twice daily regimen. Dosage adjustments are not usually required in the elderly or those with mild renal or hepatic impairment although it is probably prudent to start treatment at a low dosage and titrate upwards in such groups of patients. Numerous clinical trials have confirmed that the analgesic and anti-inflammatory efficacy of naproxen is equivalent to that of the many newer and established NSAIDs with which it has been compared. The drug is effective in many rheumatic diseases such as rheumatoid arthritis, osteoarthritis, ankylosing spondylitis and nonarticular rheumatism, in acute traumatic injury, and in the treatment of and prophylaxis against acute pain such as migraine, tension headache, postoperative pain, postpartum pain and pain associated with a variety of gynaecological procedures. Naproxen is also effective in treating the pain and associated symptoms of primary or secondary dysmenorrhoea, and decreases excessive blood loss in patients with menorrhagia. The adverse effect profile of naproxen is well established, particularly compared with that of many newer NSAIDs, and the drug is well tolerated. Thus, the efficacy and tolerability of naproxen have been clearly established over many years of clinical use, and it can therefore be considered as a first-line treatment for rheumatic diseases and various pain states.

Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 114 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United Kingdom 1 <1%
Colombia 1 <1%
Unknown 112 98%

Demographic breakdown

Readers by professional status Count As %
Student > Master 17 15%
Student > Bachelor 12 11%
Researcher 10 9%
Other 8 7%
Student > Postgraduate 6 5%
Other 24 21%
Unknown 37 32%
Readers by discipline Count As %
Medicine and Dentistry 24 21%
Pharmacology, Toxicology and Pharmaceutical Science 7 6%
Chemistry 7 6%
Psychology 5 4%
Biochemistry, Genetics and Molecular Biology 4 4%
Other 24 21%
Unknown 43 38%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 6. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 26 June 2023.
All research outputs
#5,446,210
of 25,371,288 outputs
Outputs from Drugs
#833
of 3,464 outputs
Outputs of similar age
#40,546
of 201,985 outputs
Outputs of similar age from Drugs
#336
of 1,861 outputs
Altmetric has tracked 25,371,288 research outputs across all sources so far. Compared to these this one has done well and is in the 75th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,464 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 7.9. This one has gotten more attention than average, scoring higher than 67% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 201,985 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 76% of its contemporaries.
We're also able to compare this research output to 1,861 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 68% of its contemporaries.